





TO: Regional Directors, Public Health Regions
Regional Immunization Program Managers, Health Service Regions
Directors, Local Health Departments
Immunization Managers, Local Health Departments

THRU: Jack C. Sims, Manager 
Immunization Branch

FROM: Karen Hess, Manager 
Vaccine Services Group

DATE: January 19, 2007

SUBJECT: Texas Vaccines for Children (TVFC) Program: Human Papillomavirus (HPV) Vaccine Implementation

Meningococcal Conjugate Vaccine (MCV4) two-tier removal

The Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC) have added Human Papillomavirus (HPV) as a routinely recommended vaccine. There is currently one HPV vaccine product licensed for use: GARDASIL®, manufactured by Merck & CO., Inc. licensed for females 9 – 26 years of age.

Effective immediately this vaccine is available through the Texas Vaccines for Children (TVFC) Program for implementation beginning **February 1, 2007**. The vaccine will be available to TVFC-eligible females who are 9 years through 18 years of age.

Routine vaccination with three doses of quadrivalent HPV vaccine is recommended. The first dose is given at an initial elected date, second dose two months after the first, and third dose six months after the first. Catch-up vaccination is recommended for females 13 – 18 years of age who have not been vaccinated previously or who have not completed the full vaccine series.

The minimum age and intervals for quadrivalent HPV vaccine are as follows:

<u>Minimum Age</u>	<u>Dose 1 to 2</u>	<u>Dose 2 to 3</u>
9 years old	4 weeks	12 weeks

Regional and local health departments that provide safety net vaccinations for adults are not funded at this time to provide HPV vaccine for adults.

HPV vaccine may be ordered using the TVFC Biological Order Form (C-68). A review of the targeted population numbers must be made prior to ordering HPV. Inventory and usage should be submitted monthly along with other vaccines using the Monthly Biological Report (C-33). Both of these forms have been revised to include HPV, and are included as attachments. Emergency orders are not available for initial orders of HPV.

For Medicaid billing purposes, the CPT code for HPV is 90649.

For the complete recommendations, please consult the package insert. Additional information is also available at the following websites: http://www.cdc.gov/nip/vfc/acip_resolutions/0606hpv.pdf and http://www.cdc.gov/nip/recs/provisional_rec/hpv.pdf.

Clinicians will also find the following information useful in implementing HPV vaccine:

- Quadrivalent HPV vaccine can be administered at the same visit when other age appropriate vaccines are provided, such as Tdap, Td and MCV4.
- At present, cervical cancer screening recommendations have not changed for females who receive quadrivalent HPV vaccine.
- Quadrivalent HPV vaccine can be given to females who have an equivocal or abnormal Pap test, a positive Hybrid Capture II® high risk test, or genital warts.
- Lactating women can receive quadrivalent HPV vaccine.
- Females who are immunocompromised either from disease or medication can receive quadrivalent HPV vaccine. However, the immune response to vaccination and vaccine effectiveness might be less than in females who are immunocompetent.
- Quadrivalent HPV vaccine is not recommended for use in pregnancy.
- Quadrivalent HPV vaccine is contraindicated for people with a history of immediate hypersensitivity to yeast or to any vaccine component.
- Quadrivalent HPV vaccine can be administered to females with minor acute illness (e.g., diarrhea or mild upper respiratory tract infections, with or without fever). Vaccination of people with moderate or severe acute illnesses should be deferred until after the illness improves.

MENINGOCOCCAL CONJUGATE VACCINE (MCV4)

In March of 2006, meningococcal conjugate vaccine (MCV4), Menactra® was implemented as a two-tiered vaccine, meaning that underinsured children could receive this vaccine only if they present for services in a Federally Qualified Health Center (FQHC) or Rural Health Clinic (RHC).

Effective immediately, the eligibility system for MCV4 will be simplified and all underinsured children statewide may begin receiving MCV4 at any clinic enrolled in the TVFC. Underinsured children will no longer need to be referred to a FQHC or RHC for this vaccine.

If you have questions regarding this memo or the ordering of HPV, please contact your Health Service Region.

Attachments